Logo image of ZBIO

ZENAS BIOPHARMA INC (ZBIO) Stock Fundamental Analysis

USA - NASDAQ:ZBIO - US98937L1052 - Common Stock

21.76 USD
+0.81 (+3.87%)
Last: 10/3/2025, 4:30:02 PM
21.76 USD
0 (0%)
After Hours: 10/3/2025, 4:30:02 PM
Fundamental Rating

3

Taking everything into account, ZBIO scores 3 out of 10 in our fundamental rating. ZBIO was compared to 536 industry peers in the Biotechnology industry. While ZBIO has a great health rating, there are worries on its profitability. ZBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZBIO had negative earnings in the past year.
In the past year ZBIO has reported a negative cash flow from operations.
ZBIO Yearly Net Income VS EBIT VS OCF VS FCFZBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ZBIO has a Return On Assets (-60.39%) which is comparable to the rest of the industry.
ZBIO has a Return On Equity (-73.87%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -60.39%
ROE -73.87%
ROIC N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZBIO Yearly ROA, ROE, ROICZBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZBIO Yearly Profit, Operating, Gross MarginsZBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

ZBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZBIO has been increased compared to 1 year ago.
There is no outstanding debt for ZBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZBIO Yearly Shares OutstandingZBIO Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
ZBIO Yearly Total Debt VS Total AssetsZBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 6.49 indicates that ZBIO is not in any danger for bankruptcy at the moment.
ZBIO has a better Altman-Z score (6.49) than 78.17% of its industry peers.
There is no outstanding debt for ZBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.49
ROIC/WACCN/A
WACC9.96%
ZBIO Yearly LT Debt VS Equity VS FCFZBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ZBIO has a Current Ratio of 5.23. This indicates that ZBIO is financially healthy and has no problem in meeting its short term obligations.
ZBIO has a Current ratio of 5.23. This is comparable to the rest of the industry: ZBIO outperforms 56.90% of its industry peers.
ZBIO has a Quick Ratio of 5.23. This indicates that ZBIO is financially healthy and has no problem in meeting its short term obligations.
ZBIO has a Quick ratio of 5.23. This is comparable to the rest of the industry: ZBIO outperforms 58.21% of its industry peers.
Industry RankSector Rank
Current Ratio 5.23
Quick Ratio 5.23
ZBIO Yearly Current Assets VS Current LiabilitesZBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ZBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -796.39%.
ZBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -70.00%.
EPS 1Y (TTM)-796.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.31%
Revenue 1Y (TTM)-70%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.35% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.3%
EPS Next 2Y18.4%
EPS Next 3Y14.35%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZBIO Yearly Revenue VS EstimatesZBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 10M 20M 30M 40M
ZBIO Yearly EPS VS EstimatesZBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZBIO Price Earnings VS Forward Price EarningsZBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZBIO Per share dataZBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

ZBIO's earnings are expected to grow with 14.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.4%
EPS Next 3Y14.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENAS BIOPHARMA INC

NASDAQ:ZBIO (10/3/2025, 4:30:02 PM)

After market: 21.76 0 (0%)

21.76

+0.81 (+3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)N/A N/A
Inst Owners78.01%
Inst Owner Change4.8%
Ins Owners0.8%
Ins Owner Change0%
Market Cap916.31M
Analysts89.23
Price Target33.08 (52.02%)
Short Float %16.7%
Short Ratio26.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.31%
Min EPS beat(2)-16.71%
Max EPS beat(2)29.34%
EPS beat(4)2
Avg EPS beat(4)-57.73%
Min EPS beat(4)-290.79%
Max EPS beat(4)47.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)194.12%
Min Revenue beat(2)-100%
Max Revenue beat(2)488.24%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.25%
PT rev (3m)0.44%
EPS NQ rev (1m)44.35%
EPS NQ rev (3m)29.23%
EPS NY rev (1m)21.92%
EPS NY rev (3m)15.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.09
P/FCF N/A
P/OCF N/A
P/B 3.82
P/tB 3.82
EV/EBITDA N/A
EPS(TTM)-11.06
EYN/A
EPS(NY)-4.47
Fwd EYN/A
FCF(TTM)-3.53
FCFYN/A
OCF(TTM)-3.52
OCFYN/A
SpS0.36
BVpS5.69
TBVpS5.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.39%
ROE -73.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.61%
ROA(5y)N/A
ROE(3y)-150.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.46%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.23
Quick Ratio 5.23
Altman-Z 6.49
F-Score3
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)976.2%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-796.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.31%
EPS Next Y52.3%
EPS Next 2Y18.4%
EPS Next 3Y14.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-70%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-235.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.82%
EBIT Next 3Y-25.07%
EBIT Next 5YN/A
FCF growth 1Y-292.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-292%
OCF growth 3YN/A
OCF growth 5YN/A